{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-023439","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2026-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.258072+00:00","generated_at":"2026-05-15T21:38:52.644802+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Citius subsidiary reports Phase 1 data: LYMPHIR + CAR-T shows 86% ORR, 57% CR in high-risk DLBCL","bullets":["ORR 86% at 1 month (57% CR, 29% PR) in 14 patients with relapsed/refractory DLBCL.","One-year PFS 77% (95% CI: 43–92%); one-year OS 84% (95% CI: 49–96%).","Well-tolerated: no dose-limiting toxicities, no Grade≥3 LYMPHIR-related immune AEs.","Single LYMPHIR dose depleted circulating Tregs (median reduction 24 Tregs/µL).","Study conducted at Univ of Minnesota and City of Hope; presented at 2026 Tandem Meetings."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-023439","json":"https://secwatch.observer/filing/0001213900-26-023439.json","markdown":"https://secwatch.observer/filing/0001213900-26-023439.md","text":"https://secwatch.observer/filing/0001213900-26-023439.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026023439/0001213900-26-023439-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026023439/ea0277422-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:38:52.644802+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}